Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

With a market cap of $145.7 billion, Pfizer Inc. (PFE) is a global, research-driven biopharmaceutical company, specializing ...

PFE’s Stock Performance, Rising Estimates & Attractive Valuation Pfizer’s stock has declined 6.9% in the past year compared with a decrease of 1.6% for the industry. PFE Stock Underperforms ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent years.

A few weeks back, we discussed that Pfizer’s (NYSE: PFE) stock price could rebound over a one-month period after falling 4% in a week, based on its historical performance. However, PFE stock has ...

Pfizer Inc. closed 18.77% short of its 52-week high of $31.54, which the company achieved on July 30th.

We upgraded the rating for Pfizer (PFE) stock, citing positive trends within the company and in the market, despite recent drop after Q2 earnings. Learn more here.

The pharma giant's future financial performance is a matter of debate. Pfizer (PFE -1.51%) is a stock that everyone's familiar with, but that doesn't mean that everyone agrees you should buy it.

Pfizer's depressed valuation and strong product pipeline make it a top buying opportunity for income investors in healthcare. Learn more about PFE stock here.

Investors may stay invested in PFE stock to see how its new growth drivers perform.